Mounjaro vs. Zepbound

Are Mounjaro and Zepbound the same drug?

Yes — both are tirzepatide, the same active ingredient from the same manufacturer. The differences are what each is approved for, how it's covered by insurance, and the brand name. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management and obstructive sleep apnea [1], [2].

Because the molecule is identical, they share the same mechanism, the same dose range, the same side effects, and the same boxed warning — they are not chemically different medications.

What is Mounjaro?

Mounjaro is a once-weekly injectable dual GIP/GLP-1 receptor agonist FDA-approved to improve blood sugar in adults with type 2 diabetes [1]. It is dosed from 2.5 mg up to a maximum of 15 mg once weekly.

Because tirzepatide also reduces appetite, Mounjaro produces substantial weight loss too — and is sometimes prescribed off-label for it — but it has not been FDA-approved for weight management [1]. In the diabetes trial SURPASS-2, tirzepatide lowered HbA1c by up to 2.3% and was superior to semaglutide (Ozempic) on both blood sugar and weight [4].

What is Zepbound?

Zepbound is the same molecule — tirzepatide — FDA-approved specifically for chronic weight management in adults with obesity, or overweight plus a weight-related condition, and (since 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication approved for that condition [2]. It uses the same 2.5-to-15 mg dose ladder.

In its pivotal obesity trial, SURMOUNT-1, tirzepatide produced mean weight loss of −15.0%, −19.5%, and −20.9% at the 5, 10, and 15 mg doses over 72 weeks [3].

How they work (mechanism)

Both drugs work identically because they are the same molecule. Tirzepatide is a "twincretin" that activates two gut-hormone receptors — GIP and GLP-1. It slows stomach emptying, prompts insulin when blood sugar is high, and quiets appetite and "food noise" in the brain [1], [2].

That single dual-receptor action is why tirzepatide both lowers blood sugar (the diabetes use) and reduces body weight (the obesity use) — and why the side effects are the same. The practical difference between Mounjaro and Zepbound is not how they work, but what they're approved and covered for.

Effectiveness: how much weight loss?

Because the drug is identical, the weight-loss potential is the same at the same dose — the only reason the on-label numbers come from Zepbound is that Zepbound is the version tested for weight management.

In SURMOUNT-1, adults with obesity lost a mean −20.9% of body weight at the 15 mg dose over 72 weeks, and about a third lost a quarter or more of their starting weight [3].

A person taking Mounjaro at 15 mg for diabetes is receiving the same tirzepatide at the same dose, so the appetite and weight effects are equivalent — the label and coverage differ, not the pharmacology.

What to expect: timeline

Tirzepatide works gradually, not overnight. The dose starts at 2.5 mg and steps up about every 4 weeks, so appetite eases within the first weeks while most of the weight comes off over the following months. In SURMOUNT-1, average weight loss was still building at 72 weeks — about 16–17 months — which is when the −20.9% figure was measured [3].

Loss then tends to slow and plateau. Like any obesity treatment, it works long-term: stop the drug and appetite returns and weight tends to come back, so it is intended as supervised, ongoing therapy [1], [2].

Dosing & administration

Dosing is identical: both are once-weekly subcutaneous injections started at 2.5 mg and titrated up about every 4 weeks — 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg maximum — to limit nausea [1], [2]. A given milligram dose of Mounjaro is interchangeable in effect with the same dose of Zepbound, because it is the same drug.

Side effects & safety

Side effects are the same for both because the drug is the same — predominantly gastrointestinal (nausea, diarrhea, vomiting, constipation), usually mild-to-moderate, and worst in the weeks after starting or moving up a dose [1], [2].

Serious risks & boxed warning

Both carry a boxed warning for thyroid C-cell tumors seen in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2].

Less common but serious risks include pancreatitis, gallbladder disease, acute kidney injury (often from dehydration), and — when combined with insulin or a sulfonylurea — low blood sugar [1], [2].

Who should not take it (and key cautions)

Tirzepatide is not for everyone. It is contraindicated with a personal or family history of MTC or MEN 2, or a prior serious reaction to it [1], [2]. Use caution with a history of pancreatitis or gallbladder disease.

Tirzepatide can also make oral birth control less effective — the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase [1], [2]. Tell your clinician your full history before starting either Mounjaro or Zepbound.

Cost & insurance coverage

Coverage is the real differentiator between these two. At list price both run roughly $1,000 or more per month [1], [2]. But insurers more often cover Mounjaro for diagnosed type 2 diabetes than they cover Zepbound for weight management, where coverage is inconsistent — which is a major reason some people end up on one versus the other.

Manufacturer savings programs and lower-cost self-pay vial options for Zepbound can change the real out-of-pocket figure substantially, as can a supervised medical weight-loss program like JumpstartMD's.

A note on compounded versions: compounded GLP-1 medications can be a lower-cost route, and the rules around them shifted as the recent shortages resolved [5]. Quality and physician oversight vary by source, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy — not an anonymous online seller.

JumpstartMD prescribes and supervises these medications, including compounded options where appropriate.

Can you switch from Mounjaro to Zepbound?

Yes, and it's common — usually to move onto a weight-management prescription with the same drug. Because it is the same molecule, a clinician can typically transition you at a comparable dose and continue the same titration schedule. The switch is often driven by which indication you qualify for and which your insurance will cover.

It should be supervised so the dose ladder and side-effect management are handled correctly — and you should never take both at once, since that would be a double dose of tirzepatide [2].

Which is right for you?

• You have type 2 diabetes → Mounjaro is the on-label, usually better-covered choice (and still supports weight loss) [1].
• Your primary goal is weight loss → Zepbound is the FDA-approved, on-label option with the weight-management evidence [2], [3].
• You have obstructive sleep apnea with obesity → Zepbound is FDA-approved for that specific combination [2].

Since the drug is identical, the choice usually comes down to your diagnosis and what your insurance will cover — which is exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage tirzepatide as both Mounjaro and Zepbound, including dose titration and side-effect management.